Eupraxia Pharmaceuticals (NASDAQ:EPRX) Now Covered by Analysts at William Blair

William Blair initiated coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a research report released on Monday morning, MarketBeat.com reports. The firm issued an outperform rating on the stock.

Other equities analysts have also issued research reports about the company. Zacks Research lowered Eupraxia Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. HC Wainwright reduced their target price on Eupraxia Pharmaceuticals from $12.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. Finally, Cantor Fitzgerald boosted their price target on Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a research note on Thursday, January 15th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Eupraxia Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $15.00.

Eupraxia Pharmaceuticals Stock Performance

EPRX stock opened at $7.33 on Monday. The firm has a 50 day moving average price of $8.24 and a 200-day moving average price of $6.93. Eupraxia Pharmaceuticals has a 52-week low of $2.68 and a 52-week high of $9.32. The firm has a market capitalization of $263.59 million, a price-to-earnings ratio of -7.12 and a beta of 1.27.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.21). As a group, sell-side analysts forecast that Eupraxia Pharmaceuticals will post -0.67 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Vivo Capital LLC bought a new stake in shares of Eupraxia Pharmaceuticals during the 3rd quarter valued at about $7,965,000. Ally Bridge Group NY LLC bought a new stake in Eupraxia Pharmaceuticals during the third quarter valued at about $5,398,000. Ikarian Capital LLC bought a new stake in Eupraxia Pharmaceuticals during the fourth quarter valued at about $4,606,000. Squadron Capital Management LLC purchased a new stake in Eupraxia Pharmaceuticals in the fourth quarter worth about $3,775,000. Finally, Velan Capital Investment Management LP purchased a new stake in Eupraxia Pharmaceuticals in the third quarter worth about $2,077,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.